Drugs
9
in active trials · 27 in all
Trials
35 active
67 since 2021
Drugs9
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Bispecific CD20-directed CD3 T cell engager |
Approved | Mar 2027Phase 2 trial completes | |||
| How it works | An antibody that marks B cells (a type of immune cell) for destruction | ||||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Diffuse Large B-cell Lymphoma, Follicular Lymphoma and 21 more | ||||
| Open drug page | |||||
PD-L1/4-1BB bispecific antibody |
Phase 3 | 30 Jul 2027Phase 3 trial completes | |||
| Next date | 30 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ||||
| Open drug page | |||||
— |
Phase 3 | Sep 2027Phase 3 trial completes | |||
| Next date | Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Ovarian Cancer, Endometrial Cancer and 21 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | Jan 2028Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Jan 2028 · Phase 3 trial completes | ||||
| Also tested for | Head and Neck Squamous Cell Carcinoma, Colorectal Cancer and 7 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Aug 2027Phase 1 trial completes | |||
| Next date | Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC) and 4 more | ||||
| Open drug page | |||||
— |
Phase 1 | 5 Apr 2029Phase 1 trial completes | |||
| Next date | 5 Apr 2029 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors, Urothelial Carcinoma | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2029Phase 1 trial completes | |||
| Next date | Jun 2029 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumours | ||||
| Open drug page | |||||
— |
Phase 1 | 18 Oct 2029Phase 1 trial completes | |||
| Next date | 18 Oct 2029 · Phase 1 trial completes | ||||
| Also tested for | R/R AML, R/R HR-MDS and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Jan 2031Phase 1 trial completes | |||
| Next date | Jan 2031 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
About
- No active trial
- 18 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev